Spatial tumour gene signature discriminates neoplastic from non-neoplastic compartments in colon cancer: unravelling predictive biomarkers for relapse
Authors:
Open Access
- 5 August 2023
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 21 (1) , 1-14
Abstract
Background: Opting for or against the administration of adjuvant chemotherapy in therapeutic management of stage II colon cancer remains challenging. Several studies report few survival benefits for patients treated with adjuvant therapy and additionally revealing potential side effects of overtreatment, including unnecessary exposure to chemotherapy-induced toxicities and reduced quality of life. Predictive biomarkers are urgently needed. We, therefore, hypothesise that the spatial tissue composition of relapsed and non-relapsed colon cancer stage II patients reveals relevant biomarkers. Methods: The spatial tissue composition of stage II colon cancer patients was examined by a novel spatial transcriptomics technology with sub-cellular resolution, namely in situ sequencing. A panel of 176 genes investigating specific cancer-associated processes such as apoptosis, proliferation, angiogenesis, stemness, oxidative stress, hypoxia, invasion and components of the tumour microenvironment was designed to examine differentially expressed genes in tissue of relapsed versus non-relapsed patients. Therefore, FFPE slides of 10 colon cancer stage II patients either classified as relapsed (5 patients) or non-relapsed (5 patients) were in situ sequenced and computationally analysed. Results: We identified a tumour gene signature that enables the subclassification of tissue into neoplastic and non-neoplastic compartments based on spatial expression patterns obtained through in situ sequencing. We developed a computational tool called Genes-To-Count (GTC), which automates the quantification of in situ signals, accurately mapping their position onto the spatial tissue map and automatically identifies neoplastic and non-neoplastic tissue compartments. The GTC tool was used to quantify gene expression of biological processes upregulated within the neoplastic tissue in comparison to non-neoplastic tissue and within relapsed versus non-relapsed stage II colon patients. Three differentially expressed genes (FGFR2, MMP11 and OTOP2) in the neoplastic tissue compartments of relapsed patients in comparison to non-relapsed patients were identified predicting recurrence in stage II colon cancer. Conclusions: In depth spatial in situ sequencing showed potential to provide a deeper understanding of the underlying mechanisms involved in the recurrence of disease and revealed novel potential predictive biomarkers for disease relapse in colon cancer stage II patients. Our open-access GTC-tool allowed us to accurately capture the tumour compartment and quantify spatial gene expression in colon cancer tissue.Keywords
All Related Versions
Funding Information
- Doctoral school Translational Molecular and Cellular Biosciences of Medical University of Graz
- K1 COMET Competence Center CBmed
- Bundesministerium für Klimaschutz, Umwelt, Energie, Mobilität, Innovation und Technologie
- Bundesministerium für Wissenschaft, Forschung und Wirtschaft
- Steirische Wirtschaftsförderungsgesellschaft
- Wirtschaftsagentur Wien
- Österreichische Forschungsförderungsgesellschaft
This publication has 55 references indexed in Scilit:
- Expression of CD147 and matrix metalloproteinase-11 in colorectal cancer and their relationship to clinicopathological featuresJournal of Translational Medicine, 2015
- Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancerGut, 2015
- Effects of adjuvant chemotherapy on recurrence, survival, and quality of life in stage II colon cancer patients: a 24-month follow-upSupportive Care in Cancer, 2015
- Myostatin and IGF-I signaling in end-stage human heart failure: a qRT-PCR studyJournal of Translational Medicine, 2015
- Genomic Classifier ColoPrint Predicts Recurrence in Stage II Colorectal Cancer Patients More Accurately Than Clinical FactorsThe Oncologist, 2015
- Fibroblast Growth Factor Receptor 2 IIIc as a Therapeutic Target for Colorectal Cancer CellsMolecular Cancer Therapeutics, 2012
- Fibroblast Growth Factor Receptor 2: Expression, Roles, and Potential As a Novel Molecular Target for Colorectal CancerPathology Research International, 2012
- Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis softwareBioinformatics, 2011
- Cell and tissue autofluorescence research and diagnostic applications2005
- Autofluorescence correction for fluorescence in situ hybridizationCytometry, 1995